Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT

BOCA RATON, Fla. , March 03, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced that results from a retrospective study of non-melanoma skin cancer (NMSC) patients treated with superficial radiation therapy (SRT) were published in the February 2020 issue of Journal of Drugs in Dermatology.

The study showed a non-recurrence rate of 98.9% after 85 months in 516 patients with a total of 776 NMSC lesions treated with SRT. Patients were treated with the SRT-100™ system marketed by Sensus Healthcare at four clinical sites prior to January 2015.  The article, “Long-Term Efficacy and Safety of Superficial Radiation Therapy in Subjects With Nonmelanoma Skin Cancer: A Retrospective Registry Study,” was authored by the following:

  • William Roth, M.D. of Dermatology and Dermatological Surgery, Boynton Beach, Fla.
  • Robert E. Beer, M.D. of Balfour Dermatology, Brentwood, Calif.
  • Vivek Iyengar, M.D. of Dermatology Associates, Tinley Park, Ill.
  • Thomas Bender, M.D., of Advanced Dermatology and Skin Care Centre, Mobile, Ala.
  • Isabelle Raymond, Ph.D.

Similar recurrence rates after 60 months were previously presented at the Annual Meeting of the American Academy of Dermatology in March 2019, and data from a similar retrospective study involving only the lower extremities were published in this same journal in February 2019.

An abstract of the article is available here.

“We are delighted that the powerful findings from this study were published in such an important journal, which will provide additional support to our sales representatives when discussing the benefits of SRT with potential physician customers,” said Joe Sardano, Sensus Healthcare’s chairman and chief executive officer. “Dr. Roth presented five-year topline findings from this study last year, and the complete, whole-body results are now available to physicians in this peer-reviewed journal.”

Most patients in the study population were elderly with a mean age of 79 years. Overall cure rates were consistent at 98.9% at 24, 60 and 85 months.  The Kaplan-Meier survival probability estimate was 0.989 at 24, 60 and 85 months, with a 95% confidence interval. The authors concluded that SRT is an effective and well-tolerated treatment for NMSC, and further state that these results add to the existing evidence demonstrating the safety and long-term efficacy of SRT for treating NMSC.

About the Journal of Drugs in Dermatology

The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.

It presents original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Articles are reviewed by an International Editorial Board of over 160 renowned experts.

JDD reaches around 13,760 dermatology healthcare professionals and has been recognized as the official publication of the International Society of Dermatologic Surgery (ISDS), Skin of Color Update (SOCU), and the ODAC Dermatology Aesthetic and Surgical (ODAC) conferences.

JDD is published by SanovaWorks.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted directional anisotropic radiation therapy (ART) and brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors:  our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our "Cautionary Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com